Immune Cell Therapy IKC | Ivylifesciences

Immune Cell Therapy IKC®

Ivy Life Sciences has heavily invested in the field of cell therapy in the treatment and prevention of cancer for nearly 20 years. After years of research and clinical trials, our product Immune Killer Cells Therapy (IKC therapy) is simple in principle. We extract the immune cells from the patients' blood, expand it and activate it over two weeks. The end product IKC®, contains four types of cells that can destroy cancer cells: Cytotoxic T cells, natural killer T cells, natural killer cells and γδ T cells and is injected by into the patient.

IKC®therapy has obtained international patents from the United States, Taiwan and China.

Immune Cell Therapy Applications

Liver cancer

Lung cancer

Colorectal cancer

Ovarian cancer

子宮頸癌

Multiple myeloma

Malignant lymphoma

Waldenstrom's macroglobulinemia

Peritoneal cancer

Expanded Access Eligibility:

Qualification to receive immune cell therapy fall under the Expanded Access program in Taiwan. At any Ivy Life Sciences' partner hospitals, doctors with cell therapy qualification will assess whether immune cell therapy is suitable for the patient. Then
according to different cooperative medical institutions, the following applicable conditions are divided into:

Stage IV solid cancer
Stage 1 to 3 solid cancer (ineffective after standard treatment)
Hematological malignancies (ineffective after standard treatment)
"Ineffective after standard treatment" is defined as patients who have undergone traditional treatments (surgery, chemotherapy, and radiation therapy) and are unable to obtain curative effects

In August 2018, The Ministry of Health and Welfare passed the "Measures for the Implementation or Management of Medical Instruments for Inspections of Specific Medical Techniques (referred to as the Expanded Access)" to give patients a pathway to receive cell therapy.

In May 2019, Ivy Life Sciences is proud to become the first biotechnology company in Taiwan to obtain licensing for our Cell Processing Centers,
We actively cooperate with medical institutions throughout Taiwan to implement "Expanded Access" to provide patients new options in the fight against cancer.